Open an account

Actinium Pharmaceuticals

ATNM · NYSE American

$1.40+$0.08 (+6.06%)TodayMarket closed ·
Prev close $1.32

About ATNM

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. The company is headquartered in New York City, New York and currently employs 25 full-time employees. The company went IPO on 2014-03-26. The firm is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The firm is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.

Employees
25
Headquarters
New York City, New York
Listed
Mar 26, 2014
Sector
Health Care
Industry
Biotechnology
Website
actiniumpharma.com

ATNM key statistics

Market cap
44.02M
Price-earnings ratio
3.67
Dividend yield
—
Average volume
142.01K
Volume
901.05K
Open price
$1.36
High today
$1.50
Low today
$1.35
52 Week high
$1.74
52 Week low
$0.7351

Actinium Pharmaceuticals (ATNM) at a glance

As of Oct 20, 2026, Actinium Pharmaceuticals (ATNM) shares are priced at $1.40, giving the company a market cap of 44.02M and a price-to-earnings ratio of 3.67.

Today the stock has traded between $1.35 and $1.50. The current price is 3.7% above the day's low and 6.7% below its high.

Volume so far is 901.05K shares, above the average of 142.01K shares a day.

Over the past year Actinium Pharmaceuticals has ranged from $0.7351 to $1.74, and now sits 66% of the way up that range.

Actinium Pharmaceuticals met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $0.89 per share against an estimate of -$0.221.

The average analyst price target is $4.08, 191.4% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $4.08
Low
$3.03
Now
$1.40
High
$5.25

ATNM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 132.5% on average.

  1. Q3 FY24: reported -$0.37 per share against an estimate of -$0.3427
  2. Q4 FY24: reported -$0.21 per share against an estimate of -$0.3815
  3. Q1 FY25: reported -$0.51 per share against an estimate of -$0.2831
  4. Q2 FY25: reported -$0.22 per share against an estimate of -$0.357
  5. Q3 FY25: reported -$0.16 per share against an estimate of -$0.3298
  6. Q4 FY25: reported -$0.20 per share against an estimate of -$0.1904
  7. Q1 FY26: reported -$0.18 per share against an estimate of -$0.2397
  8. Q2 FY26: reported $0.89 per share against an estimate of -$0.221

ATNM news

  • Vandana Singh

    Why Is Actinium Pharmaceuticals Stock Gaining Tuesday?

  • Press releasePRNewswire

    Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer

  • Press releasePRNewswire

    Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Press releasePRNewswire

    Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026

  • Press releasePRNewswire

    Actinium Pharmaceuticals Announces Inducement Grants to New Employees

  • Press releasePRNewswire

    Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models

  • Press releasePRNewswire

    Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development

Similar companies

Companies in the same industry as Actinium Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.